In short
GEN3017, also known as DuoBody-CD3xCD30, is an innovative drug currently undergoing clinical trials for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma. This article provides an overview of the ongoing Phase 1/2a trial, which aims to evaluate the safety, efficacy, and potential benefits of GEN3017 for patients with these challenging conditions.
At a glance
- Drug Name
- GEN3017 (DuoBody-CD3xCD30)
- Trial Phase
- Phase 1/2a
- Conditions Studied
- Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma
- Main Objectives
- Determine safe dosing, evaluate safety and tolerability, assess preliminary anti-tumor activity
- Administration Route
- Subcutaneous injection
- Key Eligibility Criteria
- CD30-positive tumors, prior treatment history, measurable disease
- Primary Endpoints
- Dose-limiting toxicities, adverse events, objective response rate
- Secondary Endpoints
- Pharmacokinetics, immunogenicity, duration of response, progression-free survival
What is GEN3017?
GEN3017, also known as DuoBody-CD3xCD30, is a new investigational drug being developed for the treatment of certain types of blood cancers. It is currently undergoing clinical trials to evaluate its safety and effectiveness in patients with specific types of lymphoma.
What conditions does GEN3017 treat?
GEN3017 is being studied for the treatment of two main types of lymphoma:
- Hodgkin lymphoma (HL): A type of cancer that starts in the lymphatic system, particularly affecting a type of white blood cell called lymphocytes.
- Non-Hodgkin lymphoma (NHL): A group of blood cancers that also start in the lymphatic system but can be more varied in their characteristics and behavior than Hodgkin lymphoma.
Specifically, the drug is being tested in patients with relapsed or refractory forms of these lymphomas. This means the cancer has either returned after initial treatment (relapsed) or has not responded well to previous treatments (refractory).
How does GEN3017 work?
GEN3017 is a type of drug called a bispecific antibody. It is designed to target two specific proteins:
- CD3: A protein found on T cells, which are a type of immune cell.
- CD30: A protein often found on the surface of lymphoma cells.
By targeting both of these proteins, GEN3017 aims to bring T cells (part of the body's immune system) close to the lymphoma cells, potentially helping the immune system to recognize and attack the cancer cells more effectively.
Current Clinical Trial
GEN3017 is currently being studied in a Phase 1/2a clinical trial. This type of trial is designed to evaluate both the safety of the drug and gather initial data on its effectiveness.
The trial is divided into two main parts:
- Dose Escalation Phase: This part aims to determine the safest and most effective dose of GEN3017.
- Expansion Phase: This part will further evaluate the effectiveness of GEN3017 at the dose determined in the first phase.
Who is eligible for the trial?
The trial has specific criteria for who can participate. Some key eligibility factors include:
- Age: Participants must be at least 18 years old in most locations. In the United States and Australia, participants as young as 16 may be eligible for certain parts of the study.
- Diagnosis: Participants must have a confirmed diagnosis of relapsed or refractory classical Hodgkin lymphoma or certain types of non-Hodgkin lymphoma.
- Previous treatments: Participants must have received at least 2 or 3 prior lines of therapy, depending on their specific situation.
- CD30 positivity: The participant's cancer must test positive for the CD30 protein.
- General health: Participants must be in relatively good overall health, as measured by specific performance scales.
There are also several factors that might exclude someone from participating, such as certain previous treatments or other health conditions.
What are the objectives of the trial?
The main objectives of the trial include:
- Determining the safest and most effective dose of GEN3017
- Evaluating the safety and tolerability of the drug
- Assessing how well GEN3017 works against the cancer (its anti-tumor activity)
- Studying how the drug moves through and is processed by the body (pharmacokinetics)
- Evaluating whether the body develops an immune response to the drug (immunogenicity)
How is GEN3017 administered?
GEN3017 is given as a subcutaneous injection. This means it is injected just under the skin, rather than into a vein. The exact dosing schedule will be determined as part of the clinical trial.
Safety Considerations
As with any investigational drug, the safety of GEN3017 is a primary focus of the clinical trial. The researchers will be closely monitoring for any side effects or adverse reactions throughout the study.
It's important to note that because GEN3017 is still in the early stages of testing, not all potential side effects may be known. Patients considering participating in the trial should discuss the potential risks and benefits thoroughly with their healthcare provider.